Description: Zenith Capital Corp., a biotechnology investment company, focuses on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with unmet medical needs. Its lead compound ZEN-3694 which is in phase 1b/2a that is in clinical development for metastatic castration resistant prostate cancer and triple negative breast cancer. The company was incorporated in 2013 and is based in Calgary, Canada.
Home Page: www.zenithepigenetics.com
4820 Richard Road SW
Calgary,
AB
T3E 6L1
Canada
Phone:
587 390 7865
Officers
| Name | Title |
|---|---|
| Mr. Donald J. McCaffrey | Chairman, President & CEO |
| Mr. Aaron Bradley Cann C.A., CPA, CBV | CFO & Secretary |
| Dr. Sanjay Lakhotia M.B.A., Ph.D. | Chief Business Officer |
| Dr. Henrik Claus Hansen Ph.D. | Senior Vice President of Operations |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | April |
| Full Time Employees: | 0 |